MYD88

Across TCGA pan-cancer cohorts, MYD88 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MYD88 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MYD88 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MYD88 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where MYD88 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.948	0.743	<.001	74	view →
CCRCC	OS	Median	All	0.718	0.945	.002	32	view →
GBM	DFS	Tertile	All	0.593	0.836	<.001	25	view →
UCEC	DFS	Tertile	III,IV	1.000	0.398	.020	16	view →
LUAD	OS	Tertile	II,III,IV	0.289	0.848	.005	5	view →
OV	DFS	Median	All	1.000	0.863	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MYD88–HNSC (OS)

Open the HNSC breakdown →